

# P J Hampton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/859882/publications.pdf>

Version: 2024-02-01

25  
papers

344  
citations

1040056

9  
h-index

839539

18  
g-index

28  
all docs

28  
docs citations

28  
times ranked

601  
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). <i>British Journal of Dermatology</i> , 2020, 183, 294-302.	1.5	85
2	A case of Schopf-Schulz-Passarge syndrome. <i>Clinical and Experimental Dermatology</i> , 2005, 30, 528-530.	1.3	45
3	Increased nuclear $\beta$ -catenin in suprabasal involved psoriatic epidermis. <i>British Journal of Dermatology</i> , 2007, 157, 1168-1177.	1.5	43
4	Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies. <i>British Journal of Dermatology</i> , 2019, 180, 195-196.	1.5	31
5	High prevalence of alcohol use disorders in patients with inflammatory skin diseases. <i>British Journal of Dermatology</i> , 2017, 177, 837-844.	1.5	24
6	An observer-blinded randomized controlled pilot trial comparing localized immersion psoralen-ultraviolet A with localized narrowband ultraviolet B for the treatment of palmar hand eczema. <i>British Journal of Dermatology</i> , 2018, 179, 63-71.	1.5	22
7	British Association of Dermatologists guidelines for the management of people with rosacea 2021*. <i>British Journal of Dermatology</i> , 2021, 185, 725-735.	1.5	20
8	Systemic medications used in treatment of common dermatological conditions: safety profile with respect to pregnancy, breast feeding and content in seminal fluid. <i>Journal of Dermatological Treatment</i> , 2019, 30, 2-18.	2.2	18
9	A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. <i>British Journal of Dermatology</i> , 2019, 181, 1265-1271.	1.5	15
10	Usability testing of MySkinSelfie: a mobile phone application for skin self-monitoring. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 73-78.	1.3	9
11	Treatment of severe, chronic hand eczema: results from a UK-wide survey. <i>Clinical and Experimental Dermatology</i> , 2017, 42, 185-188.	1.3	7
12	Telemedicine and e-Health in the Management of Psoriasis: Improving Patient Outcomes – A Narrative Review. <i>Psoriasis: Targets and Therapy</i> , 2022, Volume 12, 15-24.	2.2	7
13	Delayed hypersensitivity reaction to intralesional triamcinolone acetonide following treatment for alopecia areata. <i>Intradermal testing.. Journal of Dermatological Case Reports</i> , 2015, 9, 107-9.	1.1	5
14	Expanding treatment options for rosacea. <i>British Journal of Dermatology</i> , 2020, 183, 412-413.	1.5	4
15	A retrospective cohort study reporting rituximab treatment for 33 patients with immunobullous disease. <i>Journal of Oral Pathology and Medicine</i> , 2021, 50, 92-97.	2.7	4
16	Better definition of hidradenitis suppurativa subtypes is needed to progress disease-specific treatment outcomes. <i>British Journal of Dermatology</i> , 2017, 176, 862-863.	1.5	2
17	Case 5. <i>Clinical and Experimental Dermatology</i> , 2003, 28, 573-574.	1.3	1
18	Actikerall: an alternative to curettage for some seborrhoeic keratoses?. <i>Clinical and Experimental Dermatology</i> , 2018, 43, 198-200.	1.3	1

#	ARTICLE	IF	CITATIONS
19	A case study of an interaction design approach to pervasive healthcare. , 2018, , .		1
20	Painless unilateral ulceration of the lower leg. Clinical and Experimental Dermatology, 2009, 34, 545-546.	1.3	0
21	Hand eczema phototherapy pilot trial. British Journal of Dermatology, 2018, 179, e64-e64.	1.5	0
22	CE2 EFFICACY OF BRODALUMAB AND GUSELKUMAB IN PATIENTS WITH PLAQUE PSORIASIS WHO ARE INADEQUATE RESPONDERS TO USTEKINUMAB: A MATCHING ADJUSTED INDIRECT COMPARISON (MAIC). Value in Health, 2019, 22, S406.	0.3	0
23	18239 Secukinumab treatment results in sustained improvement in absolute PASI and drug survival: 24-month follow-up from the British Association of Dermatologists Biologics and Immunomodulators Register. Journal of the American Academy of Dermatology, 2020, 83, AB94.	1.2	0
24	New brodalumab psoriasis outcome data suggests that intermittent treatment is as effective as continuous dosing. Is it time to re-evaluate our treatment regimens?. British Journal of Dermatology, 2020, 183, 984-985.	1.5	0
25	Description of a disease activity proforma for documentation of hidradenitis suppurativa severity and distribution, and suggestions for use as a patient-reported outcome measure. Clinical and Experimental Dermatology, 2020, 45, 598-599.	1.3	0